Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Hyun Cheol ChungYoon-Koo KangZhendong ChenYuxian BaiWan Zamaniah Wan IshakByoung Yong ShimYoung Lee ParkDong-Hoe KooJianwei LuJianming XuHong Jae ChonLi-Yuan BaiShan ZengYing YuanYen-Yang ChenKangsheng GuWen Yan ZhongShu KuangChie-Schin ShihShu-Kui QinPublished in: Cancer (2021)
Definitive conclusions about the efficacy of second-line pembrolizumab in Asian patients with advanced PD-L1-positive gastric/GEJ cancer are limited because of insufficient power, but pembrolizumab was well tolerated in this patient population. Efficacy followed a trend similar to that observed in the phase 3 KEYNOTE-061 trial.
Keyphrases
- phase ii
- papillary thyroid
- open label
- end stage renal disease
- advanced non small cell lung cancer
- newly diagnosed
- clinical trial
- phase iii
- ejection fraction
- chronic kidney disease
- study protocol
- prognostic factors
- peritoneal dialysis
- case report
- randomized controlled trial
- lymph node metastasis
- young adults
- patient reported outcomes
- locally advanced
- double blind
- placebo controlled